Get the Stockscreener App
1.86
9.71%
-0.20
Pre-market:
1.92
0.06
+3.23%
Lexicon Pharmaceuticals Inc stock is traded at $1.86, with a volume of 4.44M.
It is down -9.71% in the last 24 hours and down -19.83% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
See More
Previous Close:
$2.06
Open:
$2.05
24h Volume:
4.44M
Relative Volume:
1.29
Market Cap:
$827.62M
Revenue:
$69.64M
Net Income/Loss:
$-26.09M
P/E Ratio:
-26.01
EPS:
-0.0715
Net Cash Flow:
$-38.80M
1W Performance:
-8.60%
1M Performance:
-19.83%
6M Performance:
+8.14%
1Y Performance:
+39.85%
1-Day Range:
$1.85
$2.06
1-Week Range:
$1.85
$2.195
52-Week Range:
$1.10
$2.68
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.86 | 827.62M | 69.64M | -26.09M | -38.80M | -0.0715 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-17-24 | Initiated | H.C. Wainwright | Buy |
| Apr-30-24 | Initiated | Leerink Partners | Outperform |
| Mar-07-23 | Initiated | Jefferies | Hold |
| Aug-12-22 | Initiated | Piper Sandler | Overweight |
| Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
| Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
| Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
| Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Jul-29-19 | Downgrade | Stifel | Buy → Hold |
| Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
| Jul-31-18 | Reiterated | Stifel | Buy |
| Feb-23-18 | Downgrade | Needham | Buy → Hold |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-17 | Reiterated | Wedbush | Outperform |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Aug-05-16 | Reiterated | Wedbush | Outperform |
| Aug-02-16 | Initiated | Citigroup | Buy |
| Mar-02-16 | Reiterated | Wedbush | Outperform |
| Nov-09-15 | Reiterated | Wedbush | Outperform |
| Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
| Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
| Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Pharmaceuticals stock trades near its yearly low - AD HOC NEWS
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data - finance.yahoo.com
Lexicon Pharmaceuticals stock holds steady as investors eye recent results - AD HOC NEWS
Lexicon Pharmaceuticals at H.C. Wainwright conference: catalysts ahead By Investing.com - Investing.com Australia
Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - webull.com
Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens - Investing.com
Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX? - StockInvest.us
Here's Why You Should Add LXRX Stock to Your Portfolio Now - Eastern Progress
Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
LXRX|Lexicon Pharmaceuticals Inc|Price:2.240|Chg%:-0.020 - TradingKey
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences - The Manila Times
Three New York investor conferences will hear from Lexicon - Stock Titan
Lexicon Pharmaceuticals (LXRX) Posts Positive Heart Failure Tria - GuruFocus
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure - Yahoo Finance
Sotagliflozin Linked to Fewer Heart-Failure Events in Patients With BP as Low as 100 - Stock Titan
Lexicon Pharmaceuticals Inc. (LXRX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexicon (LXRX) Results at a Glance: EPS Misses Its Estimate in the Reported Period; Post-Earnings: The Market Price Advances 0.87% at the CloseNegative Surprise Momentum - vinanet.vn
Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Advances Obesity Drug Trial, Faces Valuation Challenges - GuruFocus
Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 - marketscreener.com
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st
Lexicon (LXRX) Levels: Slides 0.41% to $2.41 in the Current Update; Technical Setup - vinanet.vn
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets (NASDAQ:LXRX) - Seeking Alpha
Lexicon Pharmaceuticals Inc (LXRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LEXICON PHARMACEUTICALS INC (LXRX) Stock Chart - ChartMill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageHere's Why - MarketBeat
LEXICON PHARMACEUTICALS, INC. SEC Filing (Aug 17, 2026) - Stock Titan
Lexicon Pharmaceuticals (LXRX) Trading Near $2.34: Support and Resistance Define Near-Term RangeGamma Squeeze - vinanet.vn
Is Lexicon’s Earnings Slide And New Share Shelf Altering The Investment Case For Lexicon Pharmaceuticals (LXRX)? - simplywall.st
Lexicon Pharmaceuticals (STU:LX31) EV-to-OCF : -14.01 (As of Aug. 15, 2026) - GuruFocus
Analysts Have Made A Financial Statement On Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Second-Quarter Report - simplywall.st
Lexicon Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-08-10 - Seeking Alpha
Renaissance Technologies LLC Increases Holdings in Lexicon Pharmaceuticals, Inc. $LXRX - MarketBeat
Lexicon Pharmaceuticals (LXRX) Declines 2.83% to $2.40 as Support Level Comes into FocusDealer Positioning - dars.gov.et
HC Wainwright Issues Positive Forecast for LXRX Earnings - MarketBeat
Lexicon Pharmaceuticals, Inc. (LXRX) stock price, news, quote and history - Yahoo Finance UK
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Why Lexicon Pharmaceuticals (LXRX) Is Up 6.9% After Q2 Revenue Collapse And New Shelf Filings - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexicon Pharmaceuticals (LXRX) Stockholders Plan to Sell 1.26M S - GuruFocus
Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highl - GuruFocus
Lexicon Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $3.86, Implies 57% Upside - TradingView
Lexicon Pharmaceuticals Inc (LXRX) (Q2 2026) Earnings Call Highlights: Zynquista NDA ... - Yahoo Finance
Lexicon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Lexicon Pharmaceuticals (Nasdaq: LXRX) files shelf to register 1.26M warrant shares - Stock Titan
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $6 - moomoo.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap Down on Disappointing Earnings - MarketBeat
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):